About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

ONO PHARMACEUTICAL CO., LTD.(4528) Summary

4528
TSE Prime
ONO PHARMACEUTICAL CO., LTD.
1,698.0
JPY
+18.0
(+1.07%)
Apr 10, 3:30 pm JST
11.56
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
13.7
PBR
0.98
Yield
4.71%
Margin Trading Ratio
11.36
Stock Price
Apr 10, 2025
Opening Apr 10, 9:00 am
1,720.0 JPY 11.67 USD
Previous Close Apr 9
1,680.0 JPY 11.55 USD
High Apr 10, 9:00 am
1,720.0 JPY 11.67 USD
Low Apr 10, 9:33 am
1,668.5 JPY 11.35 USD
Volume
3,589,900
Trading Value
6.08B JPY 0.04B USD
VWAP
1693.32 JPY 11.54 USD
Minimum Trading Value
169,800 JPY 1,156 USD
Market Cap
0.85T JPY 5.80B USD
Number of Trades
7,832
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
3,423
1-Year High May 9, 2024
13,036
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 169,900 1,718,400 10.11
Mar 28, 2025 174,900 1,784,300 10.20
Mar 21, 2025 172,000 1,752,100 10.19
Mar 14, 2025 178,300 1,812,800 10.17
Mar 7, 2025 212,700 1,766,300 8.30
Company Profile
ONO PHARMACEUTICAL CO., LTD. is a mid-tier pharmaceutical company known for its high ratio of in-house developed products, although many are nearing patent expiration. The company is experiencing growth with its new cancer drug "Opdivo".
Sector
Pharmaceuticals
ONO PHARMACEUTICAL CO., LTD. focuses primarily on prescription pharmaceuticals but also produces over-the-counter medications. The company emphasizes research and development, with a strength in innovative in-house products. It operates internationally through subsidiaries engaged in manufacturing, sales, clinical development, and in-licensing/out-licensing activities. The company has sales subsidiaries in Korea and Taiwan, and subsidiaries for clinical development and licensing activities in the United States and the United Kingdom. ONO has achieved significant success with its pioneering cancer immunotherapy drug "Opdivo". The company has also expanded into healthcare-related products, dental supplies, and digital health fields. ONO actively pursues innovation through acquisitions of pharmaceutical startups. The entire group operates under a single business segment of pharmaceuticals.